NASDAQ:TELA TELA Bio (TELA) Stock Price, News & Analysis $1.96 +0.03 (+1.55%) As of 07/8/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TELA Bio Stock (NASDAQ:TELA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TELA Bio alerts:Sign Up Key Stats Today's Range$1.92▼$2.1450-Day Range$0.95▼$2.0852-Week Range$0.86▼$5.18Volume43,036 shsAverage Volume213,534 shsMarket Capitalization$77.54 millionP/E RatioN/ADividend YieldN/APrice Target$7.25Consensus RatingModerate Buy Company Overview TELA Bio, Inc. is a clinical-stage regenerative medicine company focused on the development and commercialization of next‐generation biomaterial therapies designed to improve the repair of soft tissue across multiple surgical specialties. The company’s proprietary platform combines biologically derived materials with synthetic polymer reinforcement to create a family of hybrid tissue repair products that are intended to support tissue regeneration, restore functional integrity and reduce complications associated with existing repair solutions. The company’s lead portfolio centers on the OviTex® line of soft tissue repair products. These mesh-like scaffolds utilize a unique interwoven design of decellularized ovine extracellular matrix and permanent or resorbable polymer fibers, offering strength, biocompatibility and the potential for cellular in‐growth. OviTex products are used primarily in hernia repair and abdominal wall reconstruction, with ongoing development programs targeting orthopedic soft tissue applications, sports medicine and general surgical procedures. Founded in 2016 and headquartered in Malvern, Pennsylvania, TELA Bio completed its initial public offering in mid-2021 and has since expanded its commercial footprint across the United States and select international markets. The company leverages a direct sales force, strategic distribution partnerships and clinical collaborations to support adoption of its regenerative technologies. TELA Bio continues to advance its research pipeline through preclinical and clinical studies aimed at broadening indications and optimizing scaffold designs for various tissue repair needs. Under the leadership of Chief Executive Officer Craig Singhaus and a management team with deep experience in medical device innovation and commercialization, TELA Bio is committed to transforming soft tissue repair by delivering biomaterial therapies that address unmet clinical needs. The company maintains a collaborative environment with key opinion leaders and academic institutions to drive scientific validation and expand the evidence base for its product platform.AI Generated. May Contain Errors. Read More TELA Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreTELA MarketRank™: TELA Bio scored higher than 59% of companies evaluated by MarketBeat, and ranked 518th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingTELA Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTELA Bio has received no research coverage in the past 90 days.Read more about TELA Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TELA Bio are expected to grow in the coming year, from ($1.37) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TELA Bio is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TELA Bio is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTELA Bio has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about TELA Bio's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.51% of the float of TELA Bio has been sold short.Short Interest Ratio / Days to CoverTELA Bio has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TELA Bio has recently decreased by 12.97%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTELA Bio does not currently pay a dividend.Dividend GrowthTELA Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.51% of the float of TELA Bio has been sold short.Short Interest Ratio / Days to CoverTELA Bio has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TELA Bio has recently decreased by 12.97%, indicating that investor sentiment is improving significantly. News and Social Media1.3 / 5News Sentiment0.34 News SentimentTELA Bio has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for TELA Bio this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TELA Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of TELA Bio is held by insiders.Percentage Held by Institutions94.35% of the stock of TELA Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TELA Bio's insider trading history. Receive TELA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TELA Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TELA Stock News HeadlinesBreakeven On The Horizon For TELA Bio, Inc. (NASDAQ:TELA)July 3, 2025 | finance.yahoo.comTELA Bio Welcomes Jim Hagen with Strategic Equity GrantJune 9, 2025 | msn.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave. | Crypto Swap Profits (Ad)TELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 7, 2025 | finanznachrichten.deTELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comTELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia RepairJune 4, 2025 | tmcnet.comTELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia RepairJune 3, 2025 | globenewswire.comTELA Bio Names Jeffrey Blizard as President to Drive Strategic GrowthJune 3, 2025 | msn.comSee More Headlines TELA Stock Analysis - Frequently Asked Questions How have TELA shares performed this year? TELA Bio's stock was trading at $3.02 at the start of the year. Since then, TELA shares have decreased by 35.1% and is now trading at $1.96. How were TELA Bio's earnings last quarter? TELA Bio, Inc. (NASDAQ:TELA) issued its quarterly earnings results on Thursday, May, 8th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.04. The firm had revenue of $18.52 million for the quarter, compared to analysts' expectations of $17.35 million. TELA Bio had a negative trailing twelve-month return on equity of 402.45% and a negative net margin of 61.00%. Read the conference call transcript. When did TELA Bio IPO? TELA Bio (TELA) raised $60 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. How do I buy shares of TELA Bio? Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TELA Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that TELA Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX). Company Calendar Last Earnings5/08/2025Today7/09/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:TELA CIK1561921 Webwww.telabio.com Phone484-320-2930FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for TELA Bio$7.25 High Price Target$12.00 Low Price Target$2.00 Potential Upside/Downside+269.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.84 million Net Margins-61.00% Pretax Margin-61.13% Return on Equity-402.45% Return on Assets-62.73% Debt Debt-to-Equity Ratio2.28 Current Ratio4.22 Quick Ratio3.40 Sales & Book Value Annual Sales$69.30 million Price / Sales1.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book2.72Miscellaneous Outstanding Shares39,560,000Free Float37,696,000Market Cap$77.54 million OptionableOptionable Beta0.90 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:TELA) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TELA Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TELA Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.